The group’s principal activity is to produce bioactive signaling lipids used for treating and diagnosing human diseases. Products of the group include Sphingomab(TM), Lpathomab(TM), nSMase inhibitor, SphingoTest(TM) and ELISA-based assay. In November 2005, the group merged with Neighborhood Connections, Inc. The group operates from the United States. The revenue of the group in the year 2005, were $743,273
